

Annex I

Scientific conclusions and grounds for the variation to the terms of the Marketing Authorisation(s)

Scientific conclusions

Taking into account the PRAC Assessment Report on the PSUR(s) for cisplatin the scientific conclusions are as follows:

A meta-analysis from the literature including patients with various advanced solid tumors from 38 randomized controlled trials found an increased incidence of venous thromboembolic events in patients treated with cisplatin-based chemotherapy when compared with patients treated with non-cisplatin-based regimens. Patients receiving cisplatin-based chemotherapy had a significantly increased risk of Venous thromboembolic events.

Therefore PRAC recommends inclusion of the adverse reaction “venous thromboembolism” in the product information of all cisplatin products.

The CMDh agrees with the scientific conclusions made by the PRAC.

Grounds for the variation to the terms of the Marketing Authorisation(s)

On the basis of the scientific conclusions for cisplatin the CMDh is of the opinion that the benefit-risk balance of the medicinal product(s) containing cisplatin is unchanged subject to the proposed changes to the product information.

The CMDh reaches the position that the marketing authorisation(s) of products in the scope of this single PSUR assessment should be varied. To the extent that additional medicinal products containing cisplatin are currently authorised in the EU or are subject to future authorisation procedures in the EU, the CMDh recommends that the concerned Member States and applicant/marketing authorisation holders take due consideration of this CMDh position.

Annex II

Amendments to the product information of the nationally authorised medicinal product(s)

Amendments to be included in the relevant sections of the Product Information (new text **underlined and in bold**, deleted text ~~strike through~~)

Summary of Product Characteristics

- Section 4.8

The following adverse reaction(s) should be added under the SOC 'Vascular disorders' with a frequency 'common': **Venous thromboembolism**

Package Leaflet

4. Possible side effects

Serious side effects

Contact your doctor as soon as possible if:

You have severe pain or swelling in either of your legs, chest pain, or difficulty breathing (possibly indicating harmful blood clots in a vein) (common: may affect up to 1 in every 10 people)

Annex III

Timetable for the implementation of this position

Timetable for the implementation of this position

Adoption of CMDh position:	September 2018 CMDh meeting
Transmission to National Competent Authorities of the translations of the annexes to the position:	3 November 2018
Implementation of the position by the Member States (submission of the variation by the Marketing Authorisation Holder):	2 January 2019